Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Luca Quartuccio1, Francesca Valent2, Enrico Pasut3

  • 1Clinique de Rhumatologie, Service de Médecine (DAME), ASUFC, Université d'Udine, Udine, Italie.

Revue Du Rhumatisme (Ed. Francaise : 1993)
|May 19, 2021
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Emergence of dalbavancin non-susceptible methicillin-resistant Staphylococcus epidermidis (MRSE) in a patient treated with dalbavancin prolonged therapy: Case report, therapeutic drug monitoring and genomic characterization.

International journal of antimicrobial agents·2026
Same author

Case Commentary: When susceptibility is not enough in recurrent <i>Burkholderia cenocepacia</i> infection.

Antimicrobial agents and chemotherapy·2026
Same author

Genome sequence of a methicillin-resistant Staphylococcus epidermidis (MRSE) resistant to dalbavancin and teicoplanin isolated in Italy, 2023.

Journal of global antimicrobial resistance·2026
Same author

Gut microbiota profiling of the population residing in Friuli-Venezia Giulia through next-generation sequencing.

BMC microbiology·2026
Same author

Real-World Experience on the Use of Eravacycline at Doses of 1 mg/kg Bodyweight and Fixed Dose Strategy in Two European Tertiary Centers.

Antibiotics (Basel, Switzerland)·2026
Same author

Delphi consensus recommendations for preventing and treating cardiac implantable electronic device infections beyond current guidelines.

Scientific reports·2026

Patients with inflammatory rheumatic diseases on biologic or JAK inhibitor therapy show no increased risk of COVID-19 compared to the general population. Continued treatment and adherence to protective measures are recommended for these patients.

Area of Science:

  • Rheumatology
  • Infectious Diseases
  • Immunology

Context:

  • The COVID-19 pandemic posed risks to immunocompromised patients.
  • Patients with chronic inflammatory rheumatic diseases often require immunosuppressive therapies like biologics or JAK inhibitors.
  • Understanding COVID-19 prevalence in this specific patient group is crucial for clinical management.

Purpose:

  • To determine the prevalence of COVID-19 in adult patients with chronic inflammatory rheumatic diseases treated with biologics or JAK inhibitors.
  • To compare the COVID-19 prevalence in this cohort with the general population in the Udine province, Italy.

Summary:

  • A population-based study in Udine, Italy, included 1051 adult patients with rheumatic diseases on biologics or JAK inhibitors.
  • During the initial two months of the pandemic, 4 patients (0.38%) tested positive for COVID-19, a prevalence not significantly different from the general population (0.2%).

Related Experiment Videos

  • 15 patients presented with COVID-19 symptoms, and 47 patients were tested overall.

    • Impact:

    • The study suggests that current biologic or JAK inhibitor therapies for rheumatic diseases do not elevate COVID-19 risk.
    • Patients are encouraged to continue their essential treatments safely.
    • Reinforces the importance of preventive measures against COVID-19 for all individuals, including those with rheumatic conditions.